From Name:
From Email:
To Name:
To Email:

Optional Message:

Analyst Blog: Glaxo seeks vaccine approval

from ZACKS

GlaxoSmithKline recently announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for its cervical cancer vaccine, Cervarix. Glaxo is looking to get a two-dose schedule of Cervarix approved for use in girls between 9 to 14 years for the prevention of premalignant genital lesions including cervical, vulvar and vaginal, and cervical cancer causally related to certain oncogenic human papillomavirus types. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063